Monitoring and predicting schizophrenia relapses using voice analysis
Automatic Measurement of Antipsychotic Medication Adherence in Schizophrenia Through Speech (OBSERVSPEECH)
NA · Centre Hospitalier St Anne · NCT06613334
This study is testing a new way to help people with schizophrenia by using voice recordings to see if it can predict when they might have a relapse.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Centre Hospitalier St Anne (other) |
| Locations | 2 sites (Paris, Paris and 1 other locations) |
| Trial ID | NCT06613334 on ClinicalTrials.gov |
What this trial studies
This study aims to develop a novel approach for monitoring and predicting relapses in patients with schizophrenia by utilizing voice-based biomarkers. It involves conducting voice interviews and questionnaires through the CALLYOPE application, alongside measuring plasma antipsychotic concentrations via blood tests. The goal is to create a simple and cost-effective tool that can help in the early detection of symptoms and improve treatment adherence, ultimately reducing the risk of relapses and hospitalizations. The study focuses on patients diagnosed with schizophrenia who are stable and receiving specific antipsychotic treatments.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with schizophrenia who are stable and receiving treatment with specific antipsychotic medications.
Not a fit: Patients with neurological disorders or those unable to communicate in French may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the management of schizophrenia by preventing relapses and improving patient outcomes.
How similar studies have performed: While the use of voice analysis in psychiatric conditions is an emerging field, similar studies have shown promise in utilizing speech patterns as indicators of mental health status.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Affiliated to a social security or other social protection scheme * Diagnosed with schizophrenia according to the DSM-5 (code F20) * Stable state without duration criteria * Main treatment with risperidone or paliperidone, aripiprazole, olanzapine in oral or long-acting injectable form * Complementary treatment with an antipsychotic for anxiolytic or sedative purposes: chlorpromazine, loxapine or cyamemazine * Able to speak and read French * Able to perform speech evaluations * Able to answer questionnaires on smartphone * May be under curatorship or guardianship * Agreeing to participate in the study and with informed consent signed by the subject, as well as by the legal representative in the case of a person under curatorship or guardianship Exclusion Criteria: * Suffering from a pathology that impairs French * Suffering from a neurological pathology: multiple sclerosis, Parkinson's disease, Huntington's disease or neurodegenerative disease * Treatment with lithium salts * Anti-epileptic treatment * Participant in another study involving medication
Where this trial is running
Paris, Paris and 1 other locations
- Groupe Hospitalo-Universitaire Paris Psychiatrie et Neurosciences, Paris — Paris, Paris, France (RECRUITING)
- Groupe Hospitalo-Universitaire Paris Psychiatrie & Neurosciences — Paris, France (NOT_YET_RECRUITING)
Study contacts
- Principal investigator: Pierre De Maricourt, Dr — GHU Paris Psychiatry & Neurosciences
- Study coordinator: Pierre De Maricourt, Dr
- Email: P.DEMARICOURT@ghu-paris.fr
- Phone: (0)1 45 65 86 91
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Schizophrenia